343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
Feb 27, 2025
auto_awesome
Lizzy Lawrence, a STAT reporter, gives us an inside look at the current turmoil at the FDA, detailing the chaos of frequent staffing changes and its impact on morale. Jason Mast then discusses the acquisition of Bluebird Bio, shedding light on the company's challenges in gene therapy and its drastic fall from grace. The conversation also touches on the rise of new biotech VCs, fueled by technological advancements and the pandemic, setting the stage for a dynamic shift in the industry.
The rise of new venture capital firms led by younger investors is reshaping the biotech landscape, emphasizing innovative leadership and startup potential.
Recent turmoil at the FDA has fostered a demoralized workforce, complicating the agency's oversight amidst significant management criticisms and staff changes.
Deep dives
Emergence of New Venture Capitalists in Biotech
The landscape of venture capital investment in biotechnology has seen significant growth, particularly since 2017. An increasing number of new venture capital firms have emerged, often led by younger investors from diverse backgrounds who may lack traditional healthcare experience. This shift has been driven by factors such as the COVID-19 pandemic, which accelerated funding, and advancements in computational tools and AI that enabled new startup innovations. This trend reflects a broader transformation in the biotech sector, highlighting a move towards founder-led companies that prioritize innovative leadership.
Instability at the FDA Amid Management Changes
Recent upheavals at the FDA, including high-profile firings and rehiring processes, have created a chaotic work environment for employees. Reports indicate that the uncertainty surrounding staffing changes has led to a demoralized workforce, impacting productivity and focus among FDA staff. Lizzie Lawrence, a STAT reporter, noted that attempts to gather information about these transitions have become increasingly challenging, further complicating oversight. The situation is exacerbated by external pressures, including upcoming confirmation hearings for new leadership amidst ongoing criticisms of agency management.
Challenges Faced by Bluebird Bio
Bluebird Bio's acquisition by private equity firms underscores the financial difficulties confronting gene therapy companies. Once valued at nearly $10 billion, Bluebird has struggled with commercialization challenges and significant accumulated losses, making it difficult to sustain its business model. Despite successfully developing several gene therapies, the company faced persistent financing issues, particularly after its swift exit from the European market due to pricing negotiations. The acquisition raises questions about the future direction of Bluebird and how private equity ownership may impact the accessibility and pricing of crucial gene therapies for underserved communities.
It’s a STAT reporter two-fer guest episode. First, Lizzy Lawrence joins from D.C. to dish on the upheaval and drama taking place at the FDA. Then, we chat with Jason Mast about Bluebird Bio, its fire sale to private equity and what lies ahead for the unsettled world of genetic medicines. Before those discussions, Allison provides some insight into the “new kids” on the biotech VC block.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode